title: Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
abstract: We studied the removal of aluminoxamine (AlO) and ferrioxamine (FO) by (i) hemoperfusion/hemodialysis using an AluKart in combination with either a Cuprophan F-120 or a Hemophan FH-160 membrane, or (ii) hemodialysis with a high-flux F-60 polysulfone membrane. The same six dialysis patients underwent in a random order dialysis by the three set-ups after i.v. infusion of 30 mg/kg of desferrioxamine (DFO) during the last half an hour of the preceding dialysis session. The mean +/- SD plasma AlO and FO clearances of the AluKart combined with either a F-120 or FH-160 membrane were 194.3 +/- 25.8 ml/min (AlO) and 164.2 +/- 41.3 ml (FO) at the start of dialysis declining to respectively 76.6 +/- 27.3 and 68.5 +/- 42.6 ml/min at the end of dialysis. With a high-flux dialysis membrane the intra-dialytic plasma clearance remained constant at 81.5 +/- 6.8 ml/min for AlO and 60.0 +/- 2.8 ml/min for FO. In the presence of an AluKart combined with a FH-160 up to 84 +/- 27% and 84 +/- 19% of the available AlO and FO could be removed during a four-hour hemoperfusion/hemodialysis session. During the first hour of dialysis, respectively 59 and 58% of the total amount of AlO and FO extracted by the AluKart was removed compared to only 9 and 16% during the last hour.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Renal Unit, Sismanoglion General Hospital, Athens, Greece.
authors.forename: D M
authors.initials: DM
authors.lastname: Vasilakakis
authors.forename: P C
authors.initials: PC
authors.lastname: D'Haese
authors.forename: L V
authors.initials: LV
authors.lastname: Lamberts
authors.forename: E
authors.initials: E
authors.lastname: Lemoniatou
authors.forename: P N
authors.initials: PN
authors.lastname: Digenis
authors.forename: M E
authors.initials: ME
authors.lastname: De Broe
mesh_terms: D000328:Adult; D000535:Aluminum / Q000009:adverse effects / Q000097:blood / Q000302:isolation & purification; D002606:Charcoal; D003676:Deferoxamine / Q000097:blood / Q000302:isolation & purification* / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000097:blood / Q000302:isolation & purification*; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000097:blood / Q000302:isolation & purification*; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D005290:Ferric Compounds; D009942:Organometallic Compounds; D002606:Charcoal; C002577:ferrioxamine B; C049544:aluminoxamine; D000535:Aluminum; D003676:Deferoxamine